Entrepreneur Workshop
Heather Berger
CBO, Iolyx
IOLYX THERAPEUTICS is an early stage clinical company focused on the intersection of Immunology and Ophthalmology.
Heather Berger, Ph.D., is currently a strategic advisor to biotech companies, including as CBO of Iolyx Therapeutics. She is also an advisor to venture funds, and a board member of Design Therapeutics (DSGN). Prior, Dr. Berger was a principal at SR One, concentrating on early-stage innovative therapeutic opportunities and previously with Sofinnova Investments. Before her venture career, Heather was an equity research analyst at Wedbush Securities and an associate at JMP Securities, focused primarily on therapies for rare disease. Dr. Berger previously served on the boards of Second Genome and Entasis Therapeutics (ETTX). and was formerly a chemist at the Astellas Research Institute and adjunct faculty at the Feinberg Northwestern School of Medicine. Dr. Berger received her Ph.D. in chemistry at Northwestern University, MSc. in organic chemistry at the Weizmann Institute of Science and her B.S. from Tufts University.